Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01083368 | Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy | completed | Phase 1 / Phase 2 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01243385 |
| Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer |
| completed |
| Phase 2 |
| 44 |
| Swiss Cancer InstituteOTHER |
| 1 |
| Aug 13, 2019 |
| clinicaltrials |
| NCT00976755 | Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 37 | Swiss Cancer InstituteOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT00714753 | Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01036321 | Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness | completed | Phase 2 | 71 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT00309894 | Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | completed | Phase 2 | 49 | University of California, San FranciscoOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00774436 | Study of Focal Cryoablation in Low-Risk Prostate Cancer | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT00669162 | Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Kansas Medical CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02796898 | Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 23 | Tyme, IncINDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01881867 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01867710 | Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy | completed | Phase 2 | 164 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 4 | Jul 5, 2019 | clinicaltrials |
| NCT00003259 | Vinorelbine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 40 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00006023 | Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02057939 | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)(STREAM) | completed | Phase 2 | 38 | Duke UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | completed | Phase 2 | 25 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT00728663 | Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Swiss Cancer InstituteOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT03573011 | PSMA PET/CT for Prostate Cancer(NGP2) | completed | Phase 2 | 64 | University Hospital, GhentOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00528866 | Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | completed | Phase 2 | 80 | Radiation Therapy Oncology GroupNETWORK | 2 | Apr 24, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03081481 | Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer | completed | Phase 2 | 38 | Sophiris Bio CorpINDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT00642018 | A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | completed | Phase 2 | 154 | Eli Lilly and CompanyINDUSTRY | 4 | Apr 3, 2019 | clinicaltrials |
| NCT00274287 | GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | completed | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01685983 | A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | completed | Phase 2 | 82 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 15, 2019 | clinicaltrials |
| NCT01304485 | PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma | completed | Phase 2 | 2,000 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01553188 | AMG 386 and Abiraterone for Advanced Prostate Cancer | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01677897 | Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients(MetAb-Pro) | completed | Phase 2 | 25 | Kantonsspital GraubündenOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00311623 | Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00480090 | A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer(SLAP) | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03001895 | Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer | completed | Phase 2 | 120 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00022399 | Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 73 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01257425 | Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg(PAMIS) | completed | Phase 2 | 109 | IpsenINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02445976 | Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. | completed | Phase 2 | 197 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01664923 | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer(STRIVE) | completed | Phase 2 | 396 | PfizerINDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02409212 | Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer(PANTERA) | completed | Phase 2 | 50 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01808222 | FACBC for Recurrent Prostate Cancer | completed | Phase 2 | 25 | David M. Schuster, MDOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2019source: clinicaltrials